B
NBSE

Bailard’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Bailard’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,123
Closed -$373K – 302
2017
Q1 		$373K Hold
1,123
– – 0.03% 232
2016
Q4 		$674K Buy
1,123
+210
+23% +$222K 0.06% 183
2016
Q3 		$1.03M Hold
913
– – 0.1% 162
2016
Q2 		$1M Hold
913
– – 0.12% 157
2016
Q1 		$1.17M Buy
+913
New +$1.3M 0.16% 96

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bailard's NBSE Position: Q2 2017 in Review

Bailard sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2017, closing a stake of 1,123 shares — an estimated $373K sold.

Bailard first reported a position in NBSE in Q1 2016 and held it in 5 quarters. The position peaked at $1.17M in Q1 2016. 38 funds tracked by Wall St. Rank hold NBSE as of Q2 2017.

  • Bailard reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Bailard sold 1,123 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $373K.
  • Bailard first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2016 and held it in 5 quarters.
  • Bailard's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.17M in Q1 2016.
  • 38 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Bailard's 13F filing for Q2 2017, filed 11 Aug 2017.